Liu Y B
Department of Clinical Pharmacology, North Taiping Road Hospital, Beijing.
Zhonghua Yi Xue Za Zhi. 1993 Sep;73(9):552-4, 576.
Using dot hybridization and southern blot technique, we studied the oncogene expression in P388/ADR and L1210/cis-platinum resistant cell lines. The amplification of three oncogene probes (C-myc, v-erb-B, N-ras) controlled with beta-actin in P388/ADR resistant cells was decreased by 1.335, 1.695, 1.35-fold (P < 0.05) (drug-resistant 44.5-fold), and 2.195, 2.02, 1.854-fold (P < 0.05) (drug-resistant 23.6-fold) respectively compared with P388/0 sensitive cell lines, and 1.950-, 2.075-, 2.285-fold (P < 0.05) (drug-resistant 3.5-fold) in L1210/cis-platinum compared with L1210/0 sensitive cell lines. The three oncogene amplification in resistant cell lines was not changed when southern blot hybridage was used. These results show that the more resistant the multidrug resistant cell lines is the worse the potential multiplication and prognosis of the tumor with be.
我们运用斑点杂交和Southern印迹技术,研究了P388/ADR和L1210/顺铂耐药细胞系中的癌基因表达。与P388/0敏感细胞系相比,P388/ADR耐药细胞中三种癌基因探针(C-myc、v-erb-B、N-ras)以β-肌动蛋白为对照的扩增分别降低了1.335倍、1.695倍、1.35倍(P<0.05)(耐药44.5倍),以及2.195倍、2.02倍、1.854倍(P<0.05)(耐药23.6倍);与L1210/0敏感细胞系相比,L1210/顺铂耐药细胞中三种癌基因的扩增分别为1.950倍、2.075倍、2.285倍(P<0.05)(耐药3.5倍)。当采用Southern印迹杂交时,耐药细胞系中三种癌基因的扩增没有变化。这些结果表明,多药耐药细胞系的耐药性越强,肿瘤的潜在增殖能力和预后就越差。